The Department of Clinical Oncology conducts human studies to evaluate the effectiveness of therapies for the treatment of cancer, in order to improve the survival and quality of life of cancer patients.
The projects followed by the Department concern different types of cancer. The majority of preclinical and clinical studies focus on gynecological tumors, sarcomas, thoracic tumors (lung, mesothelioma and thymus) and pancreatic tumors.
The Department also coordinates and methodologically supports the National Health Service and various national and international Medical-Scientific Societies or Associations in the production of guidelines, from the formulation of the clinical question to the publication of recommendations.
Finally, another qualifying activity of the Department is to carry out projects of systematic review and meta-analysis of the medical-scientific literature, as well as methodological work on the main tools for the evaluation of scientific evidence.
Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
Financial Institution: Roche
Area of Research: Endometrial Cancer
A multicenter, open-label phase II trial of a customized new dosing (rapid adjustment of dose to reduce adverse reactions “radar” dosing) of Niraparib as maintenance therapy in platinum sensitive ovarian, fallopian tube or primary peritoneal recurrent cancer patients
Financial Institution: GSK
Area of Research: Ovarian Cancer
Letrozole for Estrogen/Progesterone Receptor positive low-grade Epithelial ovarian cancer. A randomized phase II trial.
Financial Institution: AIRC
Area of Research: Ovarian Cancer
Rare Cancers in Gynecologic Oncology European Network for Gynaecological Oncological Trial groups (ENGOT) Registry
Financial Institution: PharmaMar
Area of Research: Gynecological rare cancer
A phase IIIb-IV trial testing Olaparib and Bevacizumab as maintenance frontline Treatment of HRD positive ovarian tumours (IOlanTHe)
Financial Institution: Astrazeneca
Area of Research: Ovarian Cancer
Exploiting metformin plus/minus cyclic FAsting Mimicking diet (FMD) to improve the Efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-mutated lung adnocarcinoma: the FAME trial
Financial Institution: AIRC
Area of Research: NSCLC
A phase II study on TRABEctedin in combination with PPARg agonist PIOglitazone in patients with round cell myxoid liposarcomas or dedifferentiated G1 and G2 liposarcomas with stable disease in treatment with trabectedin alone
Financial Institution: AIRC - 5 per mille
Area of Research: Sarcoma
Phase III study in mCRC patients with RAS/BRAF wilde type tissue and RAS mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuximAb or BevacizumAb (LIBImAb Study)
Financial Institution: AIFA
Area of Research: Colorectal cancer
Improving treatment strategies in Thymic Epithelial Tumors: a TYME collaborative effort
Financial Institution: AIFA
Area of Research: Thymic cancer
Denosumab in EBV related nasopharyngeal carcinoma (NPC) as a model for rank-mediated immunological modulation of virus-related tumors - DERN study
Financial Institution: Amgen
Area of Research: Head and Neck cancer
The Research Center for Amyotrophic Lateral Sclerosis (ALS Center) brings together the groups that are involved in ALS research from an epidemiological, preclinicaland translational point of view.